| Unique ID issued by UMIN | UMIN000059902 |
|---|---|
| Receipt number | R000068507 |
| Scientific Title | Impact of Pre-exam GABA Administration on Stress and Psychophysiological Conditions : A Parallel-Group Comparison Trial |
| Date of disclosure of the study information | 2025/11/30 |
| Last modified on | 2025/12/01 23:22:00 |
Impact of Pre-exam GABA Administration on Stress and Psychophysiological Conditions : A Parallel-Group Comparison Trial
Impact of Pre-exam GABA Administration on Stress and Psychophysiological Conditions : A Parallel-Group Comparison Trial
Impact of Pre-exam GABA Administration on Stress and Psychophysiological Conditions : A Parallel-Group Comparison Trial
Impact of Pre-exam GABA Administration on Stress and Psychophysiological Conditions : A Parallel-Group Comparison Trial
| Japan |
healthy adult
| Adult |
Others
NO
To examine the effects of GABA intake on anxiety reduction, sleep quality, and stress reduction.
Efficacy
Exploratory
Phase II
Anxiety levels will be assessed using the State-Trait Anxiety Inventory (STAI), a validated instrument for measuring both state and trait anxiety, to evaluate changes associated with GABA capsule intake
1)Changes in sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI).
2)To Evaluate changes in sleep quality using variations in nighttime sleep proportion measured by a smartwatch.
3)To Evaluate the impact on mental health (well-being) using the WHO-5 Well-Being Index.
4)To Evaluate physiological changes in stress using the measurement results of salivary alpha-amylase.
5)To Evaluate changes in concentration by having participants self-assess using a five-point Likert scale.
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
NO
NO
YES
Central registration
2
Prevention
| Food |
Intervention group: Participants will take one GABA capsule (500 mg) once upon waking.
Control group: Participants will take one placebo capsule (containing potato starch) once upon waking.
| 18 | years-old | <= |
| 28 | years-old | > |
Male and Female
1. Those who have received sufficient explanation about the purpose and contents of this research, have the ability to provide consent, voluntarily agreed after fully understanding the details, and provided written consent to participate.
2. Individuals who are not currently receiving treatment with psychotropic medications such as anxiolytics or antidepressants.
1)Individuals who decline to participate in the study of their own volition.
2)Individuals with known allergies to any of the ingredients of the GABA capsule product.
3)Individuals deemed ineligible at the discretion of the principal
36
| 1st name | Nobuyuki |
| Middle name | |
| Last name | Wakui |
Hoshi University
Division of Applied Pharmaceutical Education and Research
142-8501
2-4-41 Ebara, Shinagawa-ku, Tokyo
03-5498-5760
n-wakui@hoshi.ac.jp
| 1st name | Nobuyuki |
| Middle name | |
| Last name | Wakui |
Hoshi University
Practical Education and Research Division
142-8501
2-4-41 Ebara, Shinagawa-ku, Tokyo
03-5498-5760
n-wakui@hoshi.ac.jp
Hoshi University
Hoshi University
Other
Institutional Review Board of Hoshi University
2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501
03-3786-1011
y-hashiguchi@hoshi.ac.jp
NO
| 2025 | Year | 11 | Month | 30 | Day |
Unpublished
Open public recruiting
| 2025 | Year | 07 | Month | 08 | Day |
| 2025 | Year | 07 | Month | 08 | Day |
| 2025 | Year | 12 | Month | 01 | Day |
| 2026 | Year | 02 | Month | 22 | Day |
| 2025 | Year | 11 | Month | 27 | Day |
| 2025 | Year | 12 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000068507